Alimera Sciences Q1 2023 Earnings Report Earnings HistoryForecast Alimera Sciences EPS ResultsActual EPS-$0.71Consensus EPS -$0.58Beat/MissMissed by -$0.13One Year Ago EPSN/AAlimera Sciences Revenue ResultsActual Revenue$13.55 millionExpected Revenue$13.00 millionBeat/MissBeat by +$550.00 thousandYoY Revenue GrowthN/AAlimera Sciences Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call ResourcesPress ReleaseALIM Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Amazon coin set to soar 25X – starting December 16th? (Ad)This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024>3-Cent Amazon Coin< Alimera Sciences Earnings HeadlinesANI Pharmaceuticals’ Record Growth and Strategic AcquisitionNovember 9, 2024 | markets.businessinsider.comANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target PriceSeptember 18, 2024 | markets.businessinsider.comFirst JFK… next Elon?Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.December 21, 2024 | Porter & Company (Ad)Alimera Sciences, Inc. (NASDAQ:ALIM): When Will It Breakeven?September 12, 2024 | finance.yahoo.comAlimera Sciences, Inc. (ALIM)September 11, 2024 | finance.yahoo.comAlimera Sciences: Deal Closing After All, CVR Still AttractiveSeptember 11, 2024 | seekingalpha.comSee More Alimera Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alimera Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alimera Sciences and other key companies, straight to your email. Email Address About Alimera SciencesAlimera Sciences (NASDAQ:ALIM), a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.View Alimera Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
